Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer
ObjectiveTo analyse positron emission tomography/ computed tomography (PET/CT) imaging and clinical data from patients with non-small cell lung cancer (NSCLC), to identify characteristics of survival beneficiaries of immune checkpoint inhibitors (ICIs) treatment and to establish a survival predictio...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1477275/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576356386340864 |
|---|---|
| author | Lu Zheng Lu Zheng Yanzhu Bian Yanzhu Bian Yujing Hu Congna Tian Xinchao Zhang Shuheng Li Xin Yang Yanan Qin |
| author_facet | Lu Zheng Lu Zheng Yanzhu Bian Yanzhu Bian Yujing Hu Congna Tian Xinchao Zhang Shuheng Li Xin Yang Yanan Qin |
| author_sort | Lu Zheng |
| collection | DOAJ |
| description | ObjectiveTo analyse positron emission tomography/ computed tomography (PET/CT) imaging and clinical data from patients with non-small cell lung cancer (NSCLC), to identify characteristics of survival beneficiaries of immune checkpoint inhibitors (ICIs) treatment and to establish a survival prediction model.MethodsA retrospective analysis was conducted on PET/CT imaging and clinical parameters of 155 NSCLC patients who underwent baseline PET/CT examination at the Department of Nuclear Medicine, Hebei General Hospital. The Kaplan–Meier curve was employed to compare progression-free survival (PFS) and overall survival (OS) between the ICIs and non-ICIs group and to assess the impact of variables on PFS and OS in the ICIs group. Multivariate Cox proportional hazards regression analysis was conducted with parameters significantly associated with survival in univariate analysis.ResultsSignificant differences were observed in PFS (χ2 = 11.910, p = 0.0006) and OS (χ2 = 8.343, p = 0.0039). Independent predictors of PFS in the ICIs group included smoking history[hazard ratio (HR) = 2.522, 95% confidence interval (CI): 1.044 ~ 6.091, p = 0.0398], SUVmax of the primary lesion(HR = 0.2376, 95%CI: 0.1018 ~ 0.5548, p = 0.0009), MTVp (HR = 0.0755, 95%CI: 0.0284 ~ 0.2003, p < 0.001), and TLGp (HR = 0.1820, 95%CI: 0.0754 ~ 0.4395, p = 0.0002). These were also independent predictors of OS in the ICIs group[HR(95%CI) were 2.729 (1.125 ~ 6.619), 0.2636 (0.1143 ~ 0.6079), 0.0715 (0.0268 ~ 0.1907), 0.2102 (0.0885 ~ 0.4992), both p < 0.05)]. Age was an additional independent predictor of OS (HR = 0.4140, 95%CI: 0.1748 ~ 0.9801, p = 0.0449).ConclusionSmoking history, primary lesion SUVmax, MTVp, and TLGp were independent predictors of PFS, whilst age, smoking history, SUVmax, MTVp, and TLGp were independent predictors of OS in the ICIs group. Patients without a history of smoking and with SUVmax ≤19.2, MTVp ≤20.745cm3, TLGp ≤158.62 g, and age ≤ 60 years benefited more from ICI treatment. |
| format | Article |
| id | doaj-art-a41c371c0b7448d3ba78000177e85b3e |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-a41c371c0b7448d3ba78000177e85b3e2025-01-31T06:40:18ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011210.3389/fmed.2025.14772751477275Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancerLu Zheng0Lu Zheng1Yanzhu Bian2Yanzhu Bian3Yujing Hu4Congna Tian5Xinchao Zhang6Shuheng Li7Xin Yang8Yanan Qin9Department of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, ChinaHebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, ChinaDepartment of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, ChinaHebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, ChinaDepartment of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, ChinaDepartment of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, ChinaDepartment of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, ChinaDepartment of Nuclear Medicine, Affiliated Hospital of Hebei University, Baoding, ChinaDepartment of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, ChinaDepartment of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, ChinaObjectiveTo analyse positron emission tomography/ computed tomography (PET/CT) imaging and clinical data from patients with non-small cell lung cancer (NSCLC), to identify characteristics of survival beneficiaries of immune checkpoint inhibitors (ICIs) treatment and to establish a survival prediction model.MethodsA retrospective analysis was conducted on PET/CT imaging and clinical parameters of 155 NSCLC patients who underwent baseline PET/CT examination at the Department of Nuclear Medicine, Hebei General Hospital. The Kaplan–Meier curve was employed to compare progression-free survival (PFS) and overall survival (OS) between the ICIs and non-ICIs group and to assess the impact of variables on PFS and OS in the ICIs group. Multivariate Cox proportional hazards regression analysis was conducted with parameters significantly associated with survival in univariate analysis.ResultsSignificant differences were observed in PFS (χ2 = 11.910, p = 0.0006) and OS (χ2 = 8.343, p = 0.0039). Independent predictors of PFS in the ICIs group included smoking history[hazard ratio (HR) = 2.522, 95% confidence interval (CI): 1.044 ~ 6.091, p = 0.0398], SUVmax of the primary lesion(HR = 0.2376, 95%CI: 0.1018 ~ 0.5548, p = 0.0009), MTVp (HR = 0.0755, 95%CI: 0.0284 ~ 0.2003, p < 0.001), and TLGp (HR = 0.1820, 95%CI: 0.0754 ~ 0.4395, p = 0.0002). These were also independent predictors of OS in the ICIs group[HR(95%CI) were 2.729 (1.125 ~ 6.619), 0.2636 (0.1143 ~ 0.6079), 0.0715 (0.0268 ~ 0.1907), 0.2102 (0.0885 ~ 0.4992), both p < 0.05)]. Age was an additional independent predictor of OS (HR = 0.4140, 95%CI: 0.1748 ~ 0.9801, p = 0.0449).ConclusionSmoking history, primary lesion SUVmax, MTVp, and TLGp were independent predictors of PFS, whilst age, smoking history, SUVmax, MTVp, and TLGp were independent predictors of OS in the ICIs group. Patients without a history of smoking and with SUVmax ≤19.2, MTVp ≤20.745cm3, TLGp ≤158.62 g, and age ≤ 60 years benefited more from ICI treatment.https://www.frontiersin.org/articles/10.3389/fmed.2025.1477275/fullPET/CTSUVnon-small cell lung cancerimmune checkpoint inhibitorsprognosis |
| spellingShingle | Lu Zheng Lu Zheng Yanzhu Bian Yanzhu Bian Yujing Hu Congna Tian Xinchao Zhang Shuheng Li Xin Yang Yanan Qin Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer Frontiers in Medicine PET/CT SUV non-small cell lung cancer immune checkpoint inhibitors prognosis |
| title | Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer |
| title_full | Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer |
| title_fullStr | Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer |
| title_full_unstemmed | Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer |
| title_short | Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer |
| title_sort | baseline 18f fdg pet ct parameters in predicting the efficacy of immunotherapy in non small cell lung cancer |
| topic | PET/CT SUV non-small cell lung cancer immune checkpoint inhibitors prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1477275/full |
| work_keys_str_mv | AT luzheng baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer AT luzheng baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer AT yanzhubian baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer AT yanzhubian baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer AT yujinghu baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer AT congnatian baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer AT xinchaozhang baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer AT shuhengli baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer AT xinyang baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer AT yananqin baseline18ffdgpetctparametersinpredictingtheefficacyofimmunotherapyinnonsmallcelllungcancer |